This document discusses the role of LH supplementation during ovarian stimulation for in vitro fertilization. It summarizes several studies that have examined the effects of recombinant LH (rLH) supplementation in different patient populations. The document indicates that rLH supplementation does not improve outcomes for most patients undergoing ovarian stimulation with GnRH analogues, but that it may benefit women with a hypo-response and women aged 36-39 years old. The document also notes that there is no evidence rLH is useful for poor responders.